target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id AXL receptor tyrosine kinase,1835,P30530,Human,BMS-777607,7953,,24794418,CCOc1ccn(c(=O)c1C(=O)Nc1ccc(c(c1)F)Oc1ccnc(c1Cl)N)c1ccc(cc1)F,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,8.96,,IC50,,1.1,,=,,,,19260711, AXL receptor tyrosine kinase,1835,P30530,Human,LDC1267,8247,,56847486,CCOc1cn(nc1C(=O)Nc1ccc(c(c1)F)Oc1ccnc2c1cc(OC)c(c2)OC)c1ccc(cc1C)F,"InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)",ISPBCAXOSOLFME-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,7.54,,IC50,,29.0,,=,,,,24553136, AXL receptor tyrosine kinase,1835,P30530,Human,gilteritinib,8708,,49803313,COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,9.1,,IC50,,0.8,,~,,,,27908881, AXL receptor tyrosine kinase,1835,P30530,Human,dubermatinib,8863,,56839178,CN1CCN(CC1)Cc1ccc(cc1)Nc1ncc(c(n1)Nc1ccccc1S(=O)(=O)N(C)C)Cl,"InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)",YUAALFPUEOYPNX-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,7.57,,IC50,,27.0,,=,,,,22247788, AXL receptor tyrosine kinase,1835,P30530,Human,merestinib,9841,,44603533,Fc1ccc(cc1)n1c(C)ccc(c1=O)C(=O)Nc1ccc(c(c1)F)Oc1cc2cnn(c2cc1c1c[nH]nc1)C,"InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)",QHADVLVFMKEIIP-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,7.96,,IC50,,11.0,,=,Inhibition of in vitro biochemical activity by EMD Millipore assay.,,,23275061, AXL receptor tyrosine kinase,1835,P30530,Human,compound 8i [PMID: 22765894],9905,,10433653,CCN1CCC(CC1)Nc1ccc2c(c1)/C(=C(/c1ncc([nH]1)C)\c1cccc(c1)F)/C(=O)N2,"InChI=1S/C26H28FN5O/c1-3-32-11-9-19(10-12-32)30-20-7-8-22-21(14-20)24(26(33)31-22)23(25-28-15-16(2)29-25)17-5-4-6-18(27)13-17/h4-8,13-15,19,30H,3,9-12H2,1-2H3,(H,28,29)(H,31,33)/b24-23-",DMQYDVBIPXAAJA-VHXPQNKSSA-N,Inhibitor,Inhibition,,,,,pIC50,,8.34,,IC50,,4.6,,=,,,,21613405, AXL receptor tyrosine kinase,1835,P30530,Human,sitravatinib,9920,,25212148,COCCNCc1ccc(nc1)c1sc2c(c1)nccc2Oc1ccc(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F,"InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)",WLAVZAAODLTUSW-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,8.82,,IC50,,1.5,,=,In a biochemical enzyme activity assay.,,,26675259, AXL receptor tyrosine kinase,1835,P30530,Human,UNC4203,10131,,118443595,CCC[C@@H](Nc1ncc2c(n1)n(cc2c1ccc(cc1)CN1CCCN(CC1)C)[C@@H]1CC[C@H](CC1)O)C,"InChI=1S/C30H44N6O/c1-4-6-22(2)32-30-31-19-27-28(21-36(29(27)33-30)25-11-13-26(37)14-12-25)24-9-7-23(8-10-24)20-35-16-5-15-34(3)17-18-35/h7-10,19,21-22,25-26,37H,4-6,11-18,20H2,1-3H3,(H,31,32,33)/t22-,25-,26-/m0/s1",HYUGTGGDEAGXJP-HRNNMHKYSA-N,Inhibitor,Inhibition,,,,,pKi,,7.4,,Ki,,40.22,,=,,,,30347155, AXL receptor tyrosine kinase,1835,P30530,Human,RIPK1 inhibitor 22b,10155,,137321158,CCn1cc(c2c1ncnc2N)c1ccc2c(c1)CCN2C(=O)Cc1cccc(c1)OC(F)(F)F,"InChI=1S/C25H22F3N5O2/c1-2-32-13-19(22-23(29)30-14-31-24(22)32)16-6-7-20-17(12-16)8-9-33(20)21(34)11-15-4-3-5-18(10-15)35-25(26,27)28/h3-7,10,12-14H,2,8-9,11H2,1H3,(H2,29,30,31)",APPXQUDJLJXULP-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,7.46,,IC50,,35.0,,=,,,,30480444, AXL receptor tyrosine kinase,1835,P30530,Human,compound 19a [PMID: 30503936],10181,,137321162,CCN1CCN(CC1)CCCOc1cc2nccc(c2cc1OC)Oc1c(F)cc(cc1F)NC(=O)NN1C(=O)CSC1c1c(F)cccc1F,"InChI=1S/C35H36F4N6O5S/c1-3-43-11-13-44(14-12-43)10-5-15-49-30-19-27-22(18-29(30)48-2)28(8-9-40-27)50-33-25(38)16-21(17-26(33)39)41-35(47)42-45-31(46)20-51-34(45)32-23(36)6-4-7-24(32)37/h4,6-9,16-19,34H,3,5,10-15,20H2,1-2H3,(H2,41,42,47)",GZVQZLVAKXRTHU-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,7.28,,IC50,,53.0,,=,,,,30503936, AXL receptor tyrosine kinase,1835,P30530,Human,belizatinib,10474,,57345941,CC(NC(=O)C1CCC(CC1)n1c(NC(=O)c2ccc(cc2)F)nc2c1cc(cc2)CN1CCC(CC1)C(O)(C)C)C,"InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)",WSTUJEXAPHIEIM-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pKd,,7.54,,Kd,,29.0,,=,Binding affinity in vitro.,,,22734674, AXL receptor tyrosine kinase,1835,P30530,Human,bemcentinib,10478,,46215462,Nc1nc(nn1c1nnc2c(c1)CCCc1c2cccc1)Nc1ccc2c(c1)CC[C@H](CC2)N1CCCC1,"InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1",KXMZDGSRSGHMMK-VWLOTQADSA-N,Inhibitor,Inhibition,,,,,pIC50,,7.85,,IC50,,14.0,,=,,,,20145120, AXL receptor tyrosine kinase,1835,P30530,Human,"compound 1 [Cruz-López et al., 2019]",10574,,145996517,N1CCN(CC1)c1ccc(cn1)c1nn2c3c1cnc(n3)NCc1nnn(c1)Cc1ccc(Cn3cc(C2)nn3)cc1,"InChI=1S/C28H28N14/c1-3-20-4-2-19(1)14-40-16-22(34-37-40)12-31-28-32-13-24-26(21-5-6-25(30-11-21)39-9-7-29-8-10-39)36-42(27(24)33-28)18-23-17-41(15-20)38-35-23/h1-6,11,13,16-17,29H,7-10,12,14-15,18H2,(H,31,32,33)",PXBYPIWEYSTETR-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,4.89,,IC50,,13000.0,,=,,,,31867559, AXL receptor tyrosine kinase,1835,P30530,Human,ningetinib,11624,,60165029,Fc1cc(ccc1Oc1ccnc2c1ccc(c2)OCC(O)(C)C)NC(=O)c1c(C)n(n(c1=O)c1ccccc1)C,"InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)",VQYYQSZNRVQLIS-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,7.96,,IC50,,11.0,,=,,,,, AXL receptor tyrosine kinase,1835,P30530,Human,zanzalintinib,12093,,139350422,Fc1ccc(cc1)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)Oc1ccnc2cc(c(cc12)C(=O)NC)OC,"InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)",JSPCKALGNNVYOO-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,8.0,,IC50,,10.0,,<,Inhibition of hAxl kinase (residues H473-A894 with Q764R) activity in vitro,,,, AXL receptor tyrosine kinase,1835,P30530,Human,"compound 6li [Chan et al., 2022]",12249,,139533572,COc1c(OCCCN2CCOCC2)cc2nccc(Oc3c(F)cc(Nc4nn(C)cc4C(=O)NC4CCCCC4)cc3)c2c1,"InChI=1S/C34H41FN6O5/c1-40-22-26(34(42)38-23-7-4-3-5-8-23)33(39-40)37-24-9-10-30(27(35)19-24)46-29-11-12-36-28-21-32(31(43-2)20-25(28)29)45-16-6-13-41-14-17-44-18-15-41/h9-12,19-23H,3-8,13-18H2,1-2H3,(H,37,39)(H,38,42)",QBRQTJMZEYORSP-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,8.8,,IC50,,1.6,,=,Inhibition of kinase activity,,,, AXL receptor tyrosine kinase,1835,P30530,Human,"compound 6li [Chan et al., 2022]",12249,,139533572,COc1c(OCCCN2CCOCC2)cc2nccc(Oc3c(F)cc(Nc4nn(C)cc4C(=O)NC4CCCCC4)cc3)c2c1,"InChI=1S/C34H41FN6O5/c1-40-22-26(34(42)38-23-7-4-3-5-8-23)33(39-40)37-24-9-10-30(27(35)19-24)46-29-11-12-36-28-21-32(31(43-2)20-25(28)29)45-16-6-13-41-14-17-44-18-15-41/h9-12,19-23H,3-8,13-18H2,1-2H3,(H,37,39)(H,38,42)",QBRQTJMZEYORSP-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pKd,,9.59,,Kd,,0.26,,=,Binding affinity for hAXL,,,, AXL receptor tyrosine kinase,1835,P30530,Human,SLC-391,12320,,118110201,C1CC1Cc1nnc(o1)c1c(ncc(c1)c1cn(nc1)C1CCNCC1)N,"InChI=1S/C19H23N7O/c20-18-16(19-25-24-17(27-19)7-12-1-2-12)8-13(9-22-18)14-10-23-26(11-14)15-3-5-21-6-4-15/h8-12,15,21H,1-7H2,(H2,20,22)",JYVSYFGHYFXYBE-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,6.3,,6.0,IC50,1000.0,,500.0,=,,,,, AXL receptor tyrosine kinase,1835,P30530,Human,adrixetinib,12375,,156440741,COc1cc2c(ccnc2cc1OC)Oc1ccc(nc1)NC(=O)c1nn(cc1OCC(F)(F)F)CCC,"InChI=1S/C25H24F3N5O5/c1-4-9-33-13-21(37-14-25(26,27)28)23(32-33)24(34)31-22-6-5-15(12-30-22)38-18-7-8-29-17-11-20(36-3)19(35-2)10-16(17)18/h5-8,10-13H,4,9,14H2,1-3H3,(H,30,31,34)",BWUUJXXFCSYLFW-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pKd,,7.0,,Kd,,100.0,,<,,,,, AXL receptor tyrosine kinase,1835,P30530,Human,canlitinib,12865,,139415233,COC1=CC2=C(C=C1OCCCCCC(O)=O)N=CC=C2OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3F,"InChI=1S/C33H31F2N3O7/c1-43-28-18-23-25(19-29(28)44-16-4-2-3-5-30(39)40)36-15-12-26(23)45-27-11-10-22(17-24(27)35)38-32(42)33(13-14-33)31(41)37-21-8-6-20(34)7-9-21/h6-12,15,17-19H,2-5,13-14,16H2,1H3,(H,37,41)(H,38,42)(H,39,40)",PCKYITPVOLEZKL-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,9.62,,IC50,,0.24,,=,,,,,